Losan Pharma GmbH

Eschbach, GermanyFEI 3004174480

Losan Pharma GmbH is a drug establishment in Eschbach, Germany, registered with the US FDA under FEI 3004174480. Its registered operations are: Labelling, Packaging. 3 EU/UK GMP certificates are matched to this site, 2 inspected within the last three years; 1 has since been withdrawn by the issuing authority. FDA has published 4 inspection outcomes for this FEI; the most recent, ended 20 Jul 2023, was classified voluntary action indicated (VAI).

Sources: FDA Drug Establishments Current Registration Site (checked 16 Nov 2026); FDA Data Dashboard (inspections); EudraGMDP; MHRA GMDP. Methodology

Cite as: PharmaTek, “Losan Pharma GmbH: FDA registration, inspection and GMP record (FEI 3004174480)”, record as of 16 Nov 2026, pharmatek.co.uk/manufacturing-sites/losan-pharma-gmbh-eschbach-3004174480

Registered operations

Business operations this establishment declares in its FDA registration. Registration is not an approval and says nothing about EU or UK GMP status.

LabellingPackaging

GMP documents matched to this site (3)

DocumentAuthorityInspectionSource
DE_BW_01_GMP_2026_0040
GMP certificate
Competent authority of Germany11 Dec 2025
within 3-year review window
EudraGMDP
DE_BW_01_GMP_2026_0038
GMP certificate
Competent authority of Germany11 Dec 2025
within 3-year review window
EudraGMDP
DE_BW_01_GMP_2024_0003
GMP certificate
Competent authority of Germany20 Jul 2023
Superseded by a newer certificate; withdrawn on 24 Mar 2026
Register note: GMP certificate has been superseded by document with the number DE_BW_01_GMP_2026_0038
EudraGMDP

A GMP document is matched to this site when its address names the site's street and its city or postcode. In our latest internal review 59 of 60 sampled matches were the right site (not yet independently reviewed; measured match quality). Check the certificate's own address before relying on it. The three-year review window is the EMA guideline default after an inspection, not an official expiry date.

FDA inspection outcomes (4)

Inspection endedOutcomeProgramme areaCitations posted
20 Jul 2023VAI · Voluntary action indicatedDrug Quality AssuranceNo
15 Apr 2021VAI · Voluntary action indicatedDrug Quality AssuranceNo
24 Jun 2015NAI · No action indicatedDrug Quality AssuranceNo
20 Jun 2013VAI · Voluntary action indicatedDrug Quality AssuranceYes

FDA Data Dashboard, joined on the FEI. NAI: no objectionable conditions found. VAI: objectionable conditions found, but not serious enough for regulatory action. OAI: regulatory or administrative action recommended. A classification describes one inspection on one date; FDA publishes it only once final and does not publish every inspection. FDA firm profile

Form 483 observations (5)

Inspection ended 20 Jun 2013: 5 observations
  • 21 CFR 211.84(d)(2) Reports of Analysis (Components)
  • 21 CFR 211.165(e) Test methods
  • 21 CFR 211.68(b) Computer control of master formula records
  • 21 CFR 211.84(b) Representative Samples
  • 21 CFR 211.100(a) Changes to Procedures Not Reviewed, Approved

FDA Data Dashboard (inspection citations), joined on the FEI. Each line is the regulation cited and FDA's short description, not the full observation text. A Form 483 lists an investigator's observations at the close of an inspection; it is not a final agency determination, and FDA does not publish citations for every inspection.

What this page does not show

  • Which substances are made here: DMFs and CEPs are filed by organisations, not sites, so we do not link substances to this site.
  • Capacity, scale, price or current availability: no regulator publishes these.
  • The full text of a Form 483 or warning letter: FDA's dashboard gives the regulation cited and a short description only.
For suppliers

Is this Losan Pharma GmbH?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.